Taysha Gene Therapies (NASDAQ:TSHA) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report published on Tuesday morning,Benzinga reports. Needham & Company LLC currently has a $6.00 target price on the stock.

Several other research analysts have also issued reports on the company. Canaccord Genuity Group lowered their target price on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, August 13th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $6.63.

Taysha Gene Therapies Stock Down 9.3 %

Shares of NASDAQ TSHA opened at $2.06 on Tuesday. Taysha Gene Therapies has a 1 year low of $1.19 and a 1 year high of $4.32. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. The firm has a market cap of $422.18 million, a PE ratio of 3.27 and a beta of 0.44. The company has a 50 day simple moving average of $1.98 and a 200 day simple moving average of $2.38.

Institutional Trading of Taysha Gene Therapies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC boosted its holdings in Taysha Gene Therapies by 328.2% in the first quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock worth $53,526,000 after acquiring an additional 14,294,445 shares in the last quarter. Artal Group S.A. raised its holdings in Taysha Gene Therapies by 0.7% during the first quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock worth $10,583,000 after buying an additional 24,444 shares during the last quarter. State Street Corp grew its holdings in shares of Taysha Gene Therapies by 4.5% during the third quarter. State Street Corp now owns 3,469,068 shares of the company’s stock valued at $6,973,000 after buying an additional 150,647 shares during the last quarter. StemPoint Capital LP acquired a new stake in shares of Taysha Gene Therapies in the 1st quarter worth about $3,122,000. Finally, Quantum Private Wealth LLC lifted its holdings in shares of Taysha Gene Therapies by 5.1% in the third quarter. Quantum Private Wealth LLC now owns 767,616 shares of the company’s stock valued at $1,543,000 after purchasing an additional 37,096 shares in the last quarter. 77.70% of the stock is owned by institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.